
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - Several of the melanocytic nevi in a "moley" child often have a similar clinical appearance, leading to the concept of a characteristic "signature nevus." Learning to recognize a patient's signature nevus aids in the evaluation of nevi, in particular those with an irregular outline of more than one color, according to Jean Bolognia, M.D.